MedTrace Logo

Same-day Antiretroviral Therapy With BIC/F/TAF

NCT04712058 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2021-01-19

No results posted yet for this study

Summary

WHO had recommened rapid ART initiation, defined as starting ART within 7 days or on the same day after HIV diagnosis, to improve HIV care continuum. Prior studies revealed that point-of-care diagnostic methods for the detection of HIV RNA can accelerate linkage to care and reduce anxiety. By shortening the interval between infectious disease physician referral, time-lag between screening and confirmatory tests, with the use of the newly developed point-of-care immunochromatographic confirmatory test, initiating a safe and potent antiretroviral therapy, BIC/F/TAF, on the same day of HIV confirmation will be feasible to improve linkage to care and to shorten the interval between HIV diagnosis and viral suppression.

Conditions

  • HIV Infections

Interventions

DRUG

Bictegravir / Emtricitabine / Tenofovir Alafenamide Oral Tablet [Biktarvy]

Biktarvy will be administered on the same day of diagnosis. The daily dosing will be continued for 48 weeks.

Sponsors & Collaborators

  • Far Eastern Memorial Hospital

    collaborator OTHER

  • Mackay Memorial Hospital

    collaborator OTHER

  • Changhua Christian Hospital

    collaborator OTHER

  • Chung Shan Medical University

    collaborator OTHER

  • National Cheng-Kung University Hospital

    collaborator OTHER

  • Chi Mei Medical Hospital

    collaborator OTHER

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    collaborator OTHER

  • Kaohsiung Municipal Ta-Tung Hospital

    collaborator UNKNOWN

  • National Taiwan University Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-20
Primary Completion
2022-12-31
Completion
2023-01-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04712058 on ClinicalTrials.gov